Social Media-Based Education on Cancer Screening Awareness in Women: A Randomized Controlled Trial
Launched by EMINE ERGIN · Apr 15, 2025
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special educational program delivered through social media can help women learn more about important cancer screenings for breast, cervical, and colorectal cancers. The goal is to see if daily educational posts on platforms like WhatsApp and Instagram can improve women's knowledge and attitudes about these screenings, making them more likely to participate in the tests that can help catch cancer early. The trial will involve 132 women aged 30 to 70 from Türkiye who have not had any cancer screenings before.
To be eligible for this trial, women must be between the ages of 30 and 70, actively use Instagram or WhatsApp, and be able to fill out online forms. Participants will receive daily educational content for eight weeks if they are in the group using social media, while another group will receive standard online education. By the end of the study, researchers will measure any changes in their knowledge and confidence regarding cancer screenings. This trial is not yet recruiting participants, but it seeks to empower women with information that could save their lives.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female participants aged 30 to 70 years
- • Use Instagram and/or WhatsApp actively
- • Literate and able to complete online forms
- • Voluntarily consent to participate
- Exclusion Criteria:
- • Diagnosed with any type of cancer
- • Have undergone previous cancer screening
About Emine Ergin
Emine Ergin is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovation. With a focus on enhancing patient outcomes, Emine Ergin collaborates with healthcare professionals and research institutions to design and implement rigorous clinical studies. The organization emphasizes ethical practices, regulatory compliance, and patient safety, ensuring that all trials are conducted with the highest standards of quality and integrity. By fostering partnerships and leveraging cutting-edge methodologies, Emine Ergin aims to contribute valuable insights to the medical community and support the development of effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Şerife Çınar, phD candidate midwife
Study Chair
Health Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported